Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device

This will be a prospective, descriptive, mono-center, non-comparative study. A sample of 30 patients who satisfy entry criteria is estimated to be appropriate to provide safety and performance data for this study.

The objectives of the study are to verify the performance and safety of the Glafkos adjustable glaucoma drainage device system. Performance will be measured assessing the possibility to adjust the intra-ocular pressure post-operatively. Safety will be measured by the incidence and severity of adverse events.

The Glafkos device will be implanted in combination with a seton tube. The implant is placed under a scleral flap, in a manner analogous to the ex-Press device (Alcon). The distal end of the draining tube is linked to a seton draining tube, which is linked to a plate placed under the extraocular muscles, creating a filtering space at the orbit (filtering bleb).

Study Overview

• Status: Unknown
• Conditions: Glaucoma
• Intervention / Treatment: Device: Glafkos drainage device

• Study Type: Interventional
• Enrollment (Anticipated): 30
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Switzerland
  • Vaud
    • Lausanne, Vaud, Switzerland, 1006
      • Recruiting
      • Montchoisi Clinic
      • Contact: André Mermoud, Prof.; Phone Number: +4121 619 37 42; Email: amermoud@gsvn.ch
      • Principal Investigator: André Mermoud, Prof. MD.
      • Sub-Investigator: Sylvain Roy, Dr. MD.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Patient must be 18 years of age or older.
2. Patient shall suffer from primary open angle glaucoma, pseudo-exfoliative glaucoma, or refractory glaucoma after failed previous filtering surgery, in the study eye. Diagnosis is based on glaucomatous optic neuropathy, Shaffer angle greater than 2 as seen on gonioscopy, and visual field defect attributed to glaucoma.
3. Eye to be treated shall be phakic or pseudophakic with no other active ocular disease or disorder except for incipiens cataract. Prior ophthalmic surgery in the study eye shall have been performed more than 3 months before enrollment in this study.
4. Patient condition is indicated for primary and secondary filtration surgery.
5. Presence of ocular hypertension defined as an intraocular corrected pressure (IOP) > 20 mmHg in the study eye, under maximally tolerated medications. The IOP level shall be obtained on 2 consecutive measurements (not taken on the same day) prior to surgery.
6. Distance Snellen best corrected visual acuity (BCVA) better than 0.6 in the fellow eye.
7. For the first three subjects the Snellen BCVA in the study eye should be 0.5 or less. In addition, the visual field defined by the Mean Defect (MD) shall be higher than 10 dB.
8. Optic neuropathy is exclusively attributed to glaucoma.
9. Patient agreed to sign the written inform consent prior to entering into the investigation.
10. Patient is able and willing to complete post-operative follow-up requirements.

Exclusion Criteria:

1. Diagnosis of neovascular glaucoma, congenital glaucoma.
2. History of previous intraocular surgery in the study eye referring to but not limited to extraocular muscles (strabismus), corneal transplant, retinal surgery.
3. Proliferative or severe non-proliferative retinopathy in either eye.
4. Congenital anomaly of the anterior chamber angle in the study eye.
5. Optic neuropathy other than glaucoma in the study eye.
6. Patient with retinal vein occlusion in the study eye.
7. Patient with retinal artery occlusion in the study eye.
8. Patient with corneal opacifications or irregularities that may interfere with the optic nerve evaluation or the IOP measurements in the study eye.
9. Patient with a history of severe eye trauma in the study eye.
10. Patient with ocular malformations such as microphthalmia in the study eye.
11. Patient with concurrent inflammatory/infective eye disorder in the study eye.
12. Patient with any sign of past or present uveitis (anterior/posterior).
13. Patient with severe systemic disease or disabling conditions such as chronic renal failure, post organ transplants.
14. Patient participating in another clinical trial or having participated in another clinical trial less than 3 months prior to entering into the investigation.
15. Patient is pregnant, breast-feeding or unable to make the decision to participate in a clinical investigation (e.g. mentally ill person, mentally handicapped person)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Glafkos device	Device: Glafkos drainage device; Other Names: eyeWatch

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number and type of SADE per patient.		24 months
IOP measurement	IOP reduced by ≥ 20% or IOP < 21 mmHg, and no IOP < 5 mmHg on two consecutive visits after 3 months.	24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Comprehensive biomicroscopy examination	Anterior and posterior segments examination using a slit-lamp biomicroscope to evaluate the condition of the cornea (epithelium, stroma, endothelium), the anterior chamber, the iris, the lens, the irido-corneal angle (cf. gonioscopy outcome 9), the vitreous body, retinal and optic nerve anatomy (cf funduscopy outcome 7).	day 1, day 7, day 14, day 28, month 2, month 3, month 6, month 12, month 18 and month 24
Assessment of easiness of surgery by surgeon	scale: 0=very easy to 5=very difficult	day 0
Assessment of easiness of adjustment	scale: 0=very easy to 5=very difficult	for 24 months
Subjective refraction	Assessment of the subjective refraction based on trial and error asking using trial lenses to achieve the best corrected visual acuity	day 7, day 14, day 28, month 2, month 3, month 6, month 12, month 18 and month 24
Funduscopy evaluation	indirect funduscopy using a 90D lens to evaluate the optic nerve anatomy (cup to disk ratio measurement) and the retinal structures	day 7, day 14, day 28, month 2, month 3, month 6, month 12, month 18 and month 24
Snellen BCVA	Distance (6m) decimal visual acuity after best optical correction was provided	day 7, day 14, day 28, month 2, month 3, month 6, month 12, month 18 and month 24
gonioscopy assessment	Irido-corneal angle assessment using the Schaffer grading scale (1-4)	day 7 and day 28

Collaborators and Investigators

• Sponsor: Rheon Medical SA

Study record dates

Study Major Dates

• Study Start: September 1, 2015
• Primary Completion (Anticipated): September 1, 2017

Study Registration Dates

• First Submitted: September 10, 2015
• First Submitted That Met QC Criteria: September 17, 2015
• First Posted (Estimate): September 18, 2015

Study Record Updates

• Last Update Posted (Estimate): September 18, 2015
• Last Update Submitted That Met QC Criteria: September 17, 2015
• Last Verified: September 1, 2015

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Ocular Hypertension; Glaucoma
• Other Study ID Numbers: 1007